Experimental siRNA therapy reduces a key driver of heart disease risk by up to 98%
Hope for Lipoprotein(a) patients
Related Articles
Reducing Missed Appointments by Addressing Social Needs
Seattle Children’s reduced missed appointments by 4% while reducing barriers to care for underrepresented communities.
FTC head raises alarm over algorithm-driven healthcare price fixing
“FTC chief warns of healthcare price fixing risks driven by technology advancements, emphasizing the use of algorithms and the agency’s focus on protecting cons
Healthpeak Properties increases 2024 FFO forecast owing to higher demand
Healthpeak Properties raised its annual funds from operations (FFO) forecast on Thursday, banking on resilient demand for its medical office and life science properties.
2024 High Five to HIPEC: Finding Hope and Health with Peritoneal Cancer
This is a free, educational event for patients with peritoneal cancers & their caregivers hosted by Fred Hutchinson Cancer Center.
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer
PURPOSE The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a…
Subscribe to Inside Medicine
Merging what I’m seeing in the ER with rigorous deep-dives on the very latest medical and public health data. I want you to know what…
Military and Veteran Benefits, News and Veteran Jobs
Military.com helps millions of military-connected Americans access military and veteran benefits and news, find jobs and enjoy military discounts.
The placebo effect: powerful, powerless or redundant?
Over the last 200 years, the placebo effect has cast a large and persuasive shadow over the medical field. In that time it has been by…
